Astra Touts $15 Billion China Investment During Starmer Trip

AstraZeneca Plc will invest $15 billion in China through 2030 to expand medicines manufacturing as well as research and development, underscoring the UK drugmaker’s deepening presence in the mainland.

The British drugmaker — whose Chief Executive Officer Pascal Soriot is currently in China as part of UK Prime Minister Keir Starmer’s official visit — said the investment will help it leverage local scientific excellence and advanced manufacturing to deliver “cutting-edge treatments to patients across China and globally.”